Product Description: Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research[1][2].
Applications: COVID-19-immunoregulation
Formula: C29H35F3N2O3.1/2C4H4O4
References: [1]Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7./[2]McGinley M, et al. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013./[3]Behrangi N, et al. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019 Jan 7;8(1):24.
CAS Number: 1234627-85-0
Molecular Weight: 574.63
Compound Purity: 99.64
Research Area: Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 12.5 mg/mL (ultrasonic)
Target: LPL Receptor
Deutsch
English
